Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of lung cancer

Environmental Health and Preventive Medicine

Volumn 7, Issue 2, 2002, Pages 47-59

  Kiyohara, Chikako ^a   Shirakawa, Taro ^b   Hopkin, Julian M ^c  

^a KYUSHU UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Drug metabolizing enzymes; Ethnic difference; Genetic polymorphism; Lung cancer; Molecular epidemiology

Indexed keywords

BIOLOGICAL MARKER; CARCINOGEN; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 ISOENZYME; ENZYME; GLUTATHIONE TRANSFERASE; ISOENZYME; XENOBIOTIC AGENT;

CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CAUCASIAN; CIGARETTE SMOKING; DETOXIFICATION; ENZYME POLYMORPHISM; ETHNIC DIFFERENCE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; INHALATION; LUNG CANCER; LUNG CARCINOGENESIS; METABOLIC ACTIVATION; MULTIGENE FAMILY; NEGRO; REVIEW; RISK FACTOR; XENOBIOTIC METABOLISM;

UNIDENTIFIED AGENTS;

EID: 0036267708     PISSN: 1342078X     EISSN: None     Source Type: Journal    
DOI: 10.1265/ehpm.2002.47     Document Type: Review

References (141)

1. Metabolism of xenobiotics
2. Nomenclature for human glutathione transferases
3. Structural distinction of rat GSH transferase subunit 10
4. Glutathione transferases stracture and catalytic activity
5. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism
6. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance
7. Genetic polymorphism of enzymes involved in xenobiotic metabolism and the risk of colorectal cancer
8. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene
9. Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene
10. A novel CYP1A1 gene polymorphism in African-Americans
11. A C4887A polymorphism in exon 7 of human CYP1A1: Population frequency, mutation linkages, and impact on lung cancer susceptibility
12. The relationship between aryl hydrocarbon hydroxylase (AHH) activity and polymorphisms of the CYP1A1 gene
13. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose
14. Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism
15. Association of CYP1A1 and microsomal epoxide hydrolase polymorphisms with lung squamous cell carcinoma
16. Polymorphism analysis of the CYP1A1 locus in Koreans: Presence of the solitary m2 allele
17. Human CYP1A1 (cytochrome P(1) 450) gene: Lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population
18. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: Lack of association with susceptibility to lung cancer in a Finnish study population
19. Lung cancer, race, and a CYP1A1 genetic polymorphism
20. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: A study on host factors in relation to age at onset, gender and histological cancer types
21. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: Exon-7 mutation (4889 A to G), and a T to C mutation in the 3′-flanking region
22. Correlation between P450 CYP1A1 inducibility, MspI genotype and lung cancer incidence
23. CYP1A1 genetic polymorphism, tobacco smoking and lung cancer risk in a French Caucasian population
24. A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility (Massachusetts, United States)
25. Cytochrome P-450 1A1 genotype in lung cancer patients and controls in Rio de Janeiro, Brazil
26. Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and AfricanAmericans
27. Lung cancer risk and CYP1A1 genotype in African Americans
28. Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients
29. Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population
30. Polymorphism of the CYP1A1 and glutathione-S-transferase gene in Korean lung cancer patients
31. The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population
32. Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism
33. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women
34. A specific African-American CYP1A1 polymorphism is associated with adenocarcinoma of the lung
35. A race-specific genetic polymorphism in the CYP1A1 gene is not associated with lung cancer in African Americans
36. CYP1A1 polymorphisms and lung cancer risk: A meta-analysis
37. Clinical relationship of pharmacogenetics
38. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians
39. Polymorphic hydroxylation of Debrisoquine in man
40. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
41. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism
42. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs
43. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
44. Family studies of mephenytoin hydroxylation deficiency
45. Nomenclature for human CYP2D6 alleles
46. Presentation with multiple cutaneous basal cell carcinomas: Association of glutathione S-transferase and cytochrome P450 genotypes with clinical phenotype
47. CYP2D6 gene polymorphism in caucasian smokers: Lung cancer susceptibility and phenotype-genotype relationships
48. Genetic polymorphism and cancer susceptibility: Fourteenth Sapporo Cancer Seminar
49. Polymorphism of human CYP2D genes involved in drug metabolism: Possible relationship to individual cancer risk
50. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County
51. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls
52. Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients
53. CYP2D6 genotyping and the association with lung cancer susceptibility
54. PCR-based CYP2D6 genotyping for Finnish lung cancer patients
55. Debrisoquin oxidation genotype and susceptibility to lung cancer
56. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls
57. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: Regulation and toxicological significance
58. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls
59. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure
60. Genetic polymorphism of CYP2D6 and lung cancer risk
61. Influence of a mutation reducing the catalytic activity of the cytochrome P450 CYP2D6 on lung cancer susceptibility
62. Ethnic differences of the primary gene defect at the cytochrome P-450 2D6
63. Genetic polymorphism of CYP2D6 in the Japanese population
64. Host factors in lung cancer risk: A review of interdisciplinary studies
65. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: Possible association with the poor metabolizer phenotype
66. Genes encoding drug-metabolizing enzymes: Possible role in human disease
67. Characterization of ethanol-inducible human liver N-nitrosodimethylamine demethylase
68. Metabolism of N-nitrosodialkylamines by human liver microsomes
69. Two common RFLPs of the human CYP2E gene
70. Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer
71. Kawajiri PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene
72. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene
73. A Taq I polymorphism in the human P450IIE1 gene on chromosome 10 (CYP2E)
74. Cytochrome P4502E1 genetic polymorphisms and lung cancer in a Taiwanese population
75. The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population
76. Genetic polymorphism of cytochrome P4502E1 in a Swedish population. Relationship to incidence of lung cancer
77. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk
78. Ethnic variation in the CYP2E1 gene: Polymorphism analysis of 695 African-Americans, European-Americans and Taiwanese
79. An Rsa I polymorphism in the CYP2E1 gene does not affect lung cancer risk in a Japanese population
80. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: In relation to p53 gene mutation
81. Gentic polymorphism of cytochrome P450: Interethnic differences and relationship to incidence of lung cancer
82. Hepatic messenger RNA contents of cytochrome P4502E1 in patients with different P4502E1 genotypes
83. Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymorphism among African-Americans and Caucasians in Los Angeles County
84. Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking and susceptibility to lung cancer
85. Characterization of soluble glutathione transferase activity in resting mononuclear leukocytes from human blood
86. Hereditary interindividual differences in the glutathione transferase activity towards transstilbene oxide in resting human mononuclear leukocytes are due to a particular isozyme(s)
87. Identification of genetic polymorphisms at the glutathione Stransferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer
88. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione Stransferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins
89. Naturally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymic properties
90. Isolation of a cDNA clone and localization of the human glutathione S-transferase 3 genes to chromosome bands 11q13 and 12q13-14
91. Lung cancer risk and genetic polymorphism at the glutathione S-transferase P1 locus in male Japanese
92. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk
93. Glutathione S-transferase M1 status and lung cancer risk: A meta-analysis
94. Isoenzyme(s) of glutathione transferase (class Mu) as a marker for the susceptibility to lung cancer: A follow up study
95. The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer
96. Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers
97. Glutathione S-transferase mu locus: Use of genotyping and phenotyping assays to assess association with lung cancer susceptibility
98. The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma
99. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer
100. Indoor coal combustion emissions, GSTM1 and GSTT1 genotypes, and lung cancer risk: A case-control study in Xuan Wei, China
101. Polymorphism in GSTM1, GSTT1, and GSTP1 and susceptibility to lung cancer in a Japanese population, Asian Pacific J
102. Dietary intake of isothiocyanates: Evidence of a joint effect with glutathione Stransferase polymorphisms in lung cancer risk
103. Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: A prospective study of men in Shanghai, China
104. Glutathione Stransferase GSTT1 genotypes and susceptibility to cancer: Studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers
105. Polymorphisms in the glutathione S-transferase class mu and theta genes interact and increase susceptibility to lung cancer in minority populations (Texas, United States)
106. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) polymorphisms and lung cancer risk among Northwestern Mediterraneans
107. Effects of glutathione S-transferases GSTM1 and GSTT1 genotypes on lung cancer risk in smokers
108. Combined effect of polymorphic GST genes on individual susceptibility to lung cancer
109. Immunohistochemical localization of glutathione S-transferases in human lung
110. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients
111. Genetic polymorphism of glutathione S-transferase P1 gene and lung cancer risk
112. Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer
113. Lung cancer risk of the GSTM1 null genotype is enhanced in the presence of the GSTP1 mutated genotype in male Japanese smokers
114. Inhibitory effects of benzyl isothiocyanate administered shortly before diethylnitrosamine or benzo[a]pyrene on pulmonary and forestomach neoplasia in A/J mice
115. Effects of alkyl chain length on the inhibition of NNK-induced lung neoplasia in A/J mice by arylalkyl isothiocyanates
116. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population
117. Combined effect of CYP1A1 inducibility and GSTM1 polymorphism on histological type of lung cancer
118. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens
119. Human CYP2A6 activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK): Mutational specificity in the gpt gene of AS52 cells
120. A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin
121. Expression and function CYP2A genes in humans
122. Identification and characterisation of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism
123. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population
124. Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method
125. The significance of the homozygous CYP2A6 deletion on nicotine metabolism: A new genotyping method of CYP2A6 using a single PCR-RFLP
126. Polymorphisms of CYP2A6 and its practical consequences
127. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population
128. Genetic variation of CYP2A6, smoking, and risk of cancer
129. Genetic polymorphism of CYP2A6 in relation to cancer
130. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae
131. Analyses of bronchial bulky DNA adduct levels and CYP2C9, GSTP1 and NQO1 genotypes in a Hungarian study population with pulmonary diseases
132. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
133. Genetic analysis of CYP2C9 polymorphism in a Japanese population
134. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California
135. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County
136. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
137. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes
138. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans
139. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese
140. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19ml in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects